1.
Cancer Cell
; 40(1): 3-5, 2022 01 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34838186
RESUMO
Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after booster dosing, and 56% of seronegative patients seroconverted post-booster vaccination. Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.